Compass Concludes full Exit for Raya and Sphinx in Rameda Pharmaceuticals
Full exit of the investors’ c.45% in Rameda Pharmaceutical after 5 years since acquisition, underscoring its ability to transform businesses and create value for partners
Full exit of the investors’ c.45% in Rameda Pharmaceutical after 5 years since acquisition, underscoring its ability to transform businesses and create value for partners
Compass exits its 51% stake in Beltone Information Technology firm after growing the business and improving its ranking in the market to first amongst peers on the EGX
Compass exits its entire stake in Beltone Financial Holding in mandatory tender offer after returning the firm to profitability and settling all outstanding debts
The acquisition comes in line with Compass strategy to diversify investment sectors and serves as a foundation for the firm’s portfolio growth over the coming years
The deal is in line with Compass’s expansion strategy in the financial services sector and reaffirms the firm’s confidence in the Egyptian economy
The acquisition gives Compass exposure to a defensive and fast-growing pharmaceutical industry with significant upside potential